Search

Your search keyword '"Khadija Tejjani"' showing total 4 results
Start Over Author "Khadija Tejjani" Topic covid-19
4 results on '"Khadija Tejjani"'

1. Decreased Passive Immunity to Respiratory Viruses through Human Milk during the COVID-19 Pandemic

Author

Marloes Grobben, Hannah G. Juncker, Karlijn van der Straten, A. H. Ayesha Lavell, Michiel Schinkel, David T. P. Buis, Maarten F. Wilbrink, Khadija Tejjani, Mathieu A. F. Claireaux, Aafke Aartse, Christianne J. M. de Groot, Dasja Pajkrt, Marije K. Bomers, Jonne J. Sikkens, Marit J. van Gils, Johannes B. van Goudoever, and Britt J. van Keulen

Subjects
antibodies, RSV, Influenza, coronaviruses, breast milk, COVID-19, Microbiology, QR1-502
Abstract

ABSTRACT Infants may develop severe viral respiratory tract infections because their immune system is still developing in the first months after birth. Human milk provides passive humoral immunity during the first months of life. During the COVID-19 pandemic, circulation of common respiratory viruses was virtually absent due to the preventative measures resulting in reduced maternal exposure. Therefore, we hypothesized that this might result in lower antibody levels in human milk during the pandemic and, subsequently, decreased protection of infants against viral respiratory tract infections. We assessed antibody levels against respiratory syncytial virus (RSV), Influenza virus, and several seasonal coronaviruses in different periods of the COVID-19 pandemic in serum and human milk using a Luminex assay. IgG levels against RSV, Influenza, HCoV-OC43, HCoV-HKU1, and HCoV-NL63 in human milk were reduced with a factor of 1.7 (P < 0.001), 2.2 (P < 0.01), 2.6 (P < 0.05), 1.4 (P < 0.01), and 2.1 (P < 0.001), respectively, since the introduction of the COVID-19 restrictions. Furthermore, we observed that human milk of mothers that experienced COVID-19 contained increased levels of IgG and IgA binding to other respiratory viruses. Passive immunity via human milk against common respiratory viruses was reduced during the COVID-19 pandemic, which may have consequences for the protection of breastfed infants against respiratory infections. IMPORTANCE Passive immunity derived from antibodies in human milk is important for protecting young infants against invading viruses. During the COVID-19 pandemic, circulation of common respiratory viruses was virtually absent due to preventative measures. In this study, we observed a decrease in human milk antibody levels against common respiratory viruses several months into the COVID-19 pandemic. This waning of antibody levels might partially explain the previously observed surge of hospitalizations of infants, mostly due to RSV, when preventative hygiene measures were lifted. Knowledge of the association between preventative measures, antibody levels in human milk and subsequent passive immunity in infants might help predict infant hospital admissions and thereby enables anticipation to prevent capacity issues. Additionally, it is important in the consideration for strategies for future lockdowns to best prevent possible consequences for vulnerable infants.

Published
2022
Full Text
View/download PDF

2. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

Author

Brent Appelman, Karlijn van der Straten, A.H. Ayesha Lavell, Michiel Schinkel, Marleen A. Slim, Meliawati Poniman, Judith A. Burger, Melissa Oomen, Khadija Tejjani, Alexander P.J. Vlaar, W. Joost Wiersinga, Yvo M. Smulders, Lonneke A. van Vught, Rogier W. Sanders, Marit J. van Gils, Marije K. Bomers, and Jonne J. Sikkens

Subjects
Vaccine, BNT162b2, SARS-CoV-2, COVID-19, Humoral immune response, Neutralisation, Medicine, Medicine (General), R5-920
Abstract

Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vaccination for individuals infected within six months. We studied whether post-vaccination immune response is equally potent in individuals infected over six months prior to vaccination. Methods: We tested serum IgG binding to SARS-CoV-2 spike protein and neutralising capacity in 110 healthcare workers, before and after both BNT162b2 messenger RNA (mRNA) vaccinations. We compared outcomes between participants with more recent infection (n = 18, median two months, IQR 2-3), with infection-vaccination interval over six months (n = 19, median nine months, IQR 9-10), and to those not previously infected (n = 73). Findings: Both recently and earlier infected participants showed comparable humoral immune responses after a single mRNA vaccination, while exceeding those of previously uninfected persons after two vaccinations with 2.5 fold (p = 0.003) and 3.4 fold (p

Published
2021
Full Text
View/download PDF

3. Differences in systemic and mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children

Author

Maya W. Keuning, Marloes Grobben, Merijn W. Bijlsma, Beau Anker, Eveline P. Berman-de Jong, Sophie Cohen, Mariet Felderhof, Anne-Elise de Groen, Femke de Groof, Maarten Rijpert, Hetty W. M. van Eijk, Khadija Tejjani, Jacqueline van Rijswijk, Maurice Steenhuis, Theo Rispens, Frans B. Plötz, Marit J. van Gils, Dasja Pajkrt, Graduate School, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Neurology, ANS - Neuroinfection & -inflammation, Neonatology, Landsteiner Laboratory, General Paediatrics, Paediatric Infectious Diseases / Rheumatology / Immunology, ARD - Amsterdam Reproduction and Development, and Molecular Microbiology

Subjects
Adult, Male, SARS-CoV-2, Immunology, COVID-19, Antibodies, Viral, saliva antibodies, Immunoglobulin A, Cross-Sectional Studies, children, antibody prevalence, Immunoglobulin G, mucosal antibody response, Prevalence, Humans, Immunology and Allergy, Female, Prospective Studies, Child, mucosal IgG
Abstract

BackgroundAs SARS-CoV-2 will likely continue to circulate, low-impact methods become more relevant to monitor antibody-mediated immunity. Saliva sampling could provide a non-invasive method with reduced impact on children. Studies reporting on the differences between systemic and mucosal humoral immunity to SARS-CoV-2 are inconsistent in adults and scarce in children. These differences may be further unraveled by exploring associations to demographic and clinical variables.MethodsTo evaluate the use of saliva antibody assays, we performed a cross-sectional cohort study by collecting serum and saliva of 223 children attending medical services in the Netherlands (irrespective of SARS-CoV-2 exposure, symptoms or vaccination) from May to October 2021. With a Luminex and a Wantai assay, we measured prevalence of SARS-CoV-2 spike (S), receptor binding domain (RBD) and nucleocapsid-specific IgG and IgA in serum and saliva and explored associations with demographic variables.FindingsThe S-specific IgG prevalence was higher in serum 39% (95% CI 32 – 45%) than in saliva 30% (95% CI 24 – 36%) (P ≤ 0.003). Twenty-seven percent (55/205) of children were S-specific IgG positive in serum and saliva, 12% (25/205) were only positive in serum and 3% (6/205) only in saliva. Vaccinated children showed a higher concordance between serum and saliva than infected children. Odds for saliva S-specific IgG positivity were higher in girls compared to boys (aOR 2.63, P = 0.012). Moreover, immunocompromised children showed lower odds for S- and RBD-specific IgG in both serum and saliva compared to healthy children (aOR 0.23 – 0.25, P ≤ 0.050).ConclusionsWe showed that saliva-based antibody assays can be useful for identifying SARS-CoV-2 humoral immunity in a non-invasive manner, and that IgG prevalence may be affected by sex and immunocompromisation. Differences between infection and vaccination, between sexes and between immunocompromised and healthy children should be further investigated and considered when choosing systemic or mucosal antibody measurement.

Published
2022
Full Text
View/download PDF

4. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

Author

Marit J. van Gils, Hugo D.G. van Willigen, Elke Wynberg, Alvin X. Han, Karlijn van der Straten, Judith A. Burger, Meliawati Poniman, Melissa Oomen, Khadija Tejjani, Joey H. Bouhuijs, Anouk Verveen, Romy Lebbink, Maartje Dijkstra, Brent Appelman, A.H. Ayesha Lavell, Tom G. Caniels, Ilja Bontjer, Lonneke A. van Vught, Alexander P.J. Vlaar, Jonne J. Sikkens, Marije K. Bomers, Colin A. Russell, Neeltje A. Kootstra, Rogier W. Sanders, Maria Prins, Godelieve J. de Bree, Menno D. de Jong, Ivette Agard, Jane Ayal, Anders Boyd, Floor Cavdar, Marianne Craanen, Udi Davidovich, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura del Grande, Joost Hartman, Nelleke Koedoot, Tjalling Leenstra, Dominique Loomans, Agata Makowska, Tom du Maine, Ilja de Man, Amy Matser, Lizenka van der Meij, Marleen van Polanen, Maria Oud, Clark Reid, Leeann Storey, Marije de Wit, Marc van Wijk, Joyce van Assem, Joost van den Aardweg, Marijne van Beek, Thyra Blankert, Brigitte Boeser-Nunnink, Eric Moll van Charante, Karel van Dort, Orlane Figaroa, Leah Frenkel, Arginell Girigorie, Jelle van Haga, Agnes Harskamp-Holwerda, Mette Hazenberg, Soemeja Hidad, Nina de Jong, Marcel Jonges, Suzanne Jurriaans, Hans Knoop, Lara Kuijt, Anja Lok, Marga Mangas Ruiz, Irma Maurer, Pythia Nieuwkerk, Ad van Nuenen, Annelou van der Veen, Bas Verkaik, Gerben-Rienk Visser, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Graduate School, APH - Mental Health, APH - Global Health, Center of Experimental and Molecular Medicine, Intensive Care Medicine, ACS - Diabetes & metabolism, APH - Personalized Medicine, APH - Health Behaviors & Chronic Diseases, ACS - Microcirculation, ACS - Pulmonary hypertension & thrombosis, Experimental Immunology, APH - Aging & Later Life, Infectious diseases, APH - Methodology, AMS - Ageing & Vitality, AMS - Tissue Function & Regeneration, Pulmonology, General practice, Public and occupational health, Medical Psychology, Adult Psychiatry, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Medical psychology, Internal medicine, Pulmonary medicine, and Hematology

Subjects
Adult, Male, Antibodies, Viral, Severity of Illness Index, Article, General Biochemistry, Genetics and Molecular Biology, response predictors, Immunogenicity, Vaccine, Neutralization Tests, Humans, Prospective Studies, BNT162 Vaccine, Aged, variants, SARS-CoV-2, Vaccination, previous infection, COVID-19, antibody response, Middle Aged, neutralization, Antibodies, Neutralizing, Treatment Outcome, mRNA vaccine, Immunoglobulin G, Spike Glycoprotein, Coronavirus, Female, BNT162b2, Follow-Up Studies
Abstract

The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies. Here, we evaluate the SARS-CoV-2 specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination, however overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than two vaccine doses in SARS-CoV-2-naive individuals., Graphical Abstract, In a prospective cohort study, van Gils et al find that a single dose of BNT162b2 mRNA vaccine up to 15 months after SARS-CoV-2 infection provides neutralizing titers exceeding two vaccine doses in SARS-CoV-2-naive individuals. This supports wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results